張文娟,苑曉超,李志紅,夏麗芳,李瑞雪,尹 飛
·論著·
產(chǎn)婦不同甲狀腺過氧化物酶抗體水平對(duì)新生兒甲狀腺功能的影響研究
張文娟,苑曉超,李志紅*,夏麗芳,李瑞雪,尹 飛
目的探討產(chǎn)婦不同甲狀腺過氧化物酶抗體(TPOAb)水平對(duì)新生兒甲狀腺功能的影響。方法2015年1月—2016年6月,選取保定市第一中心醫(yī)院收治的符合納入標(biāo)準(zhǔn)的單純TPOAb陽性產(chǎn)婦33例作為TPOAb陽性組,另選取同期于本院分娩的30例健康產(chǎn)婦作為TPOAb陰性組。所有產(chǎn)婦隨訪至產(chǎn)后6個(gè)月。將新生兒根據(jù)其母親孕晚期TPOAb水平分為N組(母親為TPOAb陰性組)、A組(母親為TPOAb陽性組),再將A組新生兒依據(jù)其母親孕晚期TPOAb水平分為A1亞組(母親孕晚期TPOAb為>30~100 U/ml,n=21)和A2亞組(母親孕晚期TPOAb>100 U/ml,n=12)。比較N組、A組新生兒出生情況評(píng)估資料,N組、A1亞組、A2亞組新生兒出生3~5 d和A1、A2亞組新生兒出生1、3個(gè)月甲狀腺功能指標(biāo)〔促甲狀腺激素(TSH)、游離甲狀腺素(FT4)水平〕、甲狀腺抗體指標(biāo)〔TPOAb、甲狀腺球蛋白抗體(TGAb)、甲狀腺球蛋白(TG)水平〕,并分析TPOAb陽性產(chǎn)婦后代出生3~5 d TSH、FT4水平與產(chǎn)婦年齡、TPOAb水平的相關(guān)性。結(jié)果N組和A組新生兒出生1 min Apgar評(píng)分、身長、體質(zhì)量比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.05)。A1、A2亞組新生兒出生3~5 d TSH、TPOAb、TGAb、TG水平均高于N組,F(xiàn)T4水平低于N組(P<0.05);A2亞組新生兒出生3~5 d TSH、TPOAb、TGAb、TG水平均高于A1亞組,F(xiàn)T4水平低于A1亞組(P<0.05)。A1亞組新生兒出生1個(gè)月失訪4例。A1、A2亞組新生兒出生1個(gè)月FT4水平比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.05);A2亞組新生兒出生1個(gè)月TSH、TPOAb、TGAb、TG水平高于A1亞組(P<0.05)。A1亞組新生兒出生3個(gè)月失訪2例。A1、A2亞組新生兒出生3個(gè)月FT4、TPOAb、TG水平比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.05)。A2亞組新生兒出生1個(gè)月TSH、TGAb水平高于A1亞組(P<0.05)。Pearson相關(guān)分析結(jié)果顯示,出生3~5 d時(shí)新生兒TSH、FT4與其母親TPOAb水平呈正相關(guān)(r值分別為0.393、0.423,P值均<0.05)。結(jié)論產(chǎn)婦單純TPOAb陽性對(duì)新生兒甲狀腺功能有影響,且產(chǎn)婦TPOAb高水平對(duì)新生兒甲狀腺功能的影響時(shí)間更長。
妊娠;甲狀腺過氧化物酶抗體;甲狀腺功能試驗(yàn);嬰兒
近幾年,隨著孕婦甲狀腺功能篩查工作的普遍開展,甲狀腺疾病已成為孕婦常見疾病之一。目前國內(nèi)外研究發(fā)現(xiàn),甲狀腺過氧化物酶抗體(TPOAb)對(duì)孕婦甲狀腺功能、妊娠結(jié)局、新生兒智力發(fā)育及行為均有不良影響[1-3]。但既往研究大多未詳細(xì)分析產(chǎn)婦單純TPOAb陽性對(duì)新生兒甲狀腺功能的影響,因此尚不清楚TPOAb是否通過胎盤直接影響新生兒甲狀腺功能,進(jìn)而影響其智力發(fā)育。本研究旨在探討產(chǎn)婦不同TPOAb水平對(duì)新生兒甲狀腺功能的影響,旨在為臨床提供一定參考。
1.1 一般資料 2015年1月—2016年6月,選取保定市第一中心醫(yī)院收治的符合納入標(biāo)準(zhǔn)的單純TPOAb陽性產(chǎn)婦33例作為TPOAb陽性組。納入標(biāo)準(zhǔn):(1)年齡20~29歲;(2)單胎自然妊娠;(3)整個(gè)孕期均在保定市第一中心醫(yī)院就診并隨訪;(4)孕早期(孕12周以前)、孕中期(孕12~28周)及孕晚期(孕28周后)游離三碘甲狀腺原氨酸(FT3)、促甲狀腺激素(TSH)、游離甲狀腺素(FT4)、反三碘甲狀腺原氨酸(rT3)均在參考范圍內(nèi),其中TSH參考范圍依據(jù)《妊娠和產(chǎn)后甲狀腺疾病診治指南》[4]中的相關(guān)規(guī)定(孕早期:0.1~2.5 mU/L,孕中期:0.2~3.0 mU/L,孕晚期:0.3~3.0 mU/L),F(xiàn)T4參考范圍依據(jù)本院放免室修訂的妊娠期參考范圍(11.00~32.00 pmol/L);(5)孕早期及孕晚期促甲狀腺素受體抗體(TRAb)、甲狀腺球蛋白抗體(TGAb)及甲狀腺球蛋白(TG)為陰性且TPOAb為陽性者;其中TRAb、TGAb、TG陰性診斷標(biāo)準(zhǔn)為:TRAb≤30 U/ml,TGAb≤30 U/ml,TG≤50 U/ml;TPOAb陽性診斷標(biāo)準(zhǔn)為TPOAb>30 U/ml。排除標(biāo)準(zhǔn):(1)服用過影響甲狀腺功能的藥物;(2)有妊娠劇吐、腦垂體疾病、卵巢腫瘤等疾病史;(3)有甲狀腺疾病史;(4)有慢性肝、腎疾病,心血管疾病,自身免疫性疾病病史;(5)有妊娠期高血壓、糖尿病等產(chǎn)科并發(fā)癥;(6)有胎停育、早產(chǎn)、巨大兒、胎兒生長受限、新生兒畸形等不良妊娠結(jié)局。另選取同期于本院分娩的30例健康產(chǎn)婦作為TPOAb陰性組。本研究已通過保定市第一中心醫(yī)院倫理委員會(huì)審查,受試者知情并同意新生兒篩查甲狀腺功能。TPOAb陰性組、TPOAb陽性組產(chǎn)婦年齡、孕前體質(zhì)指數(shù)、孕期增加的體質(zhì)量比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.01,見表1)。

Table1 Comparison of basic data between TPOAb negative group and TPOAb positive group

組別例數(shù)年齡(歲)孕前體質(zhì)指數(shù)(kg/m2)孕期增加的體質(zhì)量(kg)TPOAb陰性組3025.5±2.722.9±2.514.3±2.7TPOAb陽性組3326.0±2.523.7±2.114.1±3.1t值0.7651.4750.216P值0.4470.1450.829
注:TPOAb=甲狀腺過氧化物酶抗體
1.2 研究方法 所有產(chǎn)婦隨訪至產(chǎn)后6個(gè)月。收集新生兒出生情況評(píng)估資料(評(píng)估資料由2名高年資臨床婦產(chǎn)科醫(yī)師共同評(píng)估得出,包括出生1 min Apgar評(píng)分、體質(zhì)量、身長等指標(biāo));抽取新生兒出生后3~5 d、1個(gè)月、3個(gè)月靜脈血進(jìn)行甲狀腺功能指標(biāo)及甲狀腺抗體指標(biāo)篩查。
將新生兒根據(jù)其母親孕晚期TPOAb水平分為N組(母親為TPOAb陰性組)、A組(母親為TPOAb陽性組),再將A組新生兒依據(jù)其母親孕晚期TPOAb水平分為A1亞組(母親孕晚期TPOAb為>30~100 U/ml)和A2亞組(母親孕晚期TPOAb>100 U/ml)。
1.3 檢測方法 采用電化學(xué)發(fā)光免疫分析法檢測血清TSH、FT4水平及TPOAb、TGAb、TG水平(深圳市新產(chǎn)業(yè)生物醫(yī)學(xué)工程股份有限公司,配套試劑盒)。TSH試劑的敏感性<0.001 μU/ml,批內(nèi)變異系數(shù)≤5%,批間變異系數(shù)≤10%。TPOAb、TGAb試劑的敏感性分別<0.38 U/ml、0.50 U/ml,批內(nèi)變異系數(shù)均≤5%,批間變異系數(shù)均≤10%。
1.4 觀察指標(biāo) 比較N組、A組新生兒出生情況評(píng)估資料,N組、A1亞組、A2亞組新生兒出生3~5 d時(shí),A1、A2亞組新生兒出生1、3個(gè)月時(shí)甲狀腺功能指標(biāo)(TSH、FT4水平)、甲狀腺抗體指標(biāo)(TPOAb、TGAb、TG水平),并分析TPOAb陽性產(chǎn)婦后代出生3~5 d TSH、FT4水平與產(chǎn)婦年齡、TPOAb水平的相關(guān)性。

2.1 N組、A組新生兒出生情況評(píng)估資料比較 N組、A組新生兒出生1 min Apgar評(píng)分、身長、體質(zhì)量比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.05,見表2)。

Table2 Comparison of Apgar score 1 min after birth and height,weight between two neonatal groups

組別例數(shù)出生1minApgar評(píng)分(分)身長(cm)體質(zhì)量(kg)N組309.8±0.450.6±1.93.3±0.4A組339.9±0.350.8±2.03.2±0.5t值0.6050.4900.539P值0.5470.6260.592
注:N組=母親為TPOAb陰性組,A組=母親為TPOAb陽性組
2.2 3組新生兒出生3~5 d甲狀腺功能指標(biāo)、甲狀腺抗體指標(biāo)比較 3組新生兒出生3~5 d TSH、FT4、TPOAb、TGAb、TG水平比較,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。A1、A2亞組新生兒出生3~5 d TSH、TPOAb、TGAb、TG水平均高于N組,F(xiàn)T4水平低于N組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05);A2亞組新生兒出生3~5 d TSH、TPOAb、TGAb、TG水平均高于A1亞組,F(xiàn)T4水平低于A1亞組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05,見表3)。
2.3 兩亞組新生兒出生1、3個(gè)月甲狀腺功能指標(biāo)、甲狀腺抗體指標(biāo)比較 A1亞組新生兒出生1個(gè)月失訪4例。A1、A2亞組新生兒出生1個(gè)月FT4水平比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.05);A2亞組新生兒出生1個(gè)月TSH、TPOAb、TGAb、TG水平高于A1亞組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05,見表4)。
A1亞組新生兒出生3個(gè)月失訪2例。A1、A2亞組新生兒出生3個(gè)月FT4、TPOAb、TG水平比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.05);A2亞組新生兒出生1個(gè)月TSH、TGAb水平高于A1亞組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05,見表5)。

Table3 Comparison of the TSH,FT4,TPOAb,TGAb and TG levels among the 3 groups neonate in the 3-5 days after birth

組別例數(shù)TSH(mU/L)FT4(pmol/L)TPOAb(U/ml)TGAb(U/ml)TG(U/ml)N組302.8±1.514.6±3.217.4±8.216.3±9.633.9±27.8A1亞組214.3±1.6a12.5±3.0a24.5±4.6a26.2±3.1a83.4±25.4aA2亞組126.4±1.7ab12.2±2.9ab231.9±10.0ab69.2±6.7ab103.8±18.4abF值23.1423.9063757.649215.5941.569P值<0.0010.025<0.001<0.001<0.001
注:母親孕晚期TPOAb為>30~100 U/ml為A1亞組;母親孕晚期TPOAb>100 U/ml為A2亞組;TSH=促甲狀腺激素,F(xiàn)T4=游離甲狀腺素,TPOAb=甲狀腺過氧化物酶抗體,TGAb=甲狀腺球蛋白抗體,TG=甲狀腺球蛋白;與N組比較,aP<0.05;與A1亞組比較,bP<0.05

Table4 Comparison of the thyroid function index and thyroid antibody index between A1 and A2 subgroups in the first month after birth

組別例數(shù)TSH(mU/L)FT4(pmol/L)TPOAb(U/ml)TGAb(U/ml)TG(U/ml)A1亞組173.6±1.613.4±3.534.2±4.938.4±16.617.6±16.4A2亞組125.3±1.913.6±3.086.2±13.078.3±15.459.0±20.2t值2.5160.21515.1236.5846.185P值0.0180.832<0.001<0.001<0.001

Table5 Comparison of the thyroid function index and thyroid antibody index between A1 and A2 subgroups in the thirdmonth after birth

組別例數(shù)TSH(mU/L)FT4(pmol/L)TPOAb(U/ml)TGAb(U/ml)TG(U/ml)A1亞組152.4±1.615.1±2.224.6±1.823.0±15.913.1±13.5A2亞組123.4±1.214.7±2.425.3±1.450.3±21.615.2±14.6t值2.1640.4531.1133.8060.372P值0.0490.6540.2760.0010.713
2.4 TPOAb陽性產(chǎn)婦后代出生3~5 d TSH、FT4水平與產(chǎn)婦年齡、TPOAb水平的關(guān)系 Pearson相關(guān)分析結(jié)果顯示,出生3~5 d時(shí)新生兒TSH、FT4水平與其母親TPOAb水平呈正相關(guān)(r值分別為0.393、0.423,P值均<0.05);出生3~5 d時(shí)新生兒TSH、T4水平與其母親年齡無直線相關(guān)關(guān)系(r值分別為0.071、0.129,P值均>0.05)。
TPOAb是甲狀腺微粒體抗體(AMA)的主要成分,是一組針對(duì)多種不同抗原決定簇的多克隆抗體,以IgG型為主,可抑制過氧化物酶的活性,從而破壞甲狀腺功能[5]。雖然從母體接觸TPOAb陽性的新生兒并未發(fā)生永久性甲狀腺功能減退,但多項(xiàng)研究表明,妊娠期TPOAb陽性可對(duì)新生兒智力發(fā)育及行為產(chǎn)生不利影響[6]。然而,尚不清楚TPOAb是否通過胎盤直接影響新生兒神經(jīng)系統(tǒng)發(fā)育,是否是先影響孕婦甲狀腺功能后再對(duì)新生兒產(chǎn)生不利影響。本研究旨在探討孕婦單純TPOAb陽性對(duì)新生兒甲狀腺功能的影響。
3.1 TPOAb與新生兒臨床特征 本研究結(jié)果顯示,TPOAb陽性組與TPOAb陰性組產(chǎn)婦娩出的新生兒出生1 min Apgar評(píng)分、身長、體質(zhì)量間無差異。既往研究表明,孕婦TPOAb陽性可導(dǎo)致流產(chǎn)、早產(chǎn)、胎膜早破、胎兒窘迫等不良妊娠結(jié)局[1-2],而本研究可能因觀察時(shí)間較短,未發(fā)現(xiàn)不良妊娠結(jié)局,且從N組和A組新生兒出生1 min Apgar評(píng)分、身長、體質(zhì)量比較結(jié)果來看,單純TPOAb陽性未對(duì)新生兒產(chǎn)生不良影響,與陳東等[7]研究結(jié)果相似。
3.2 TPOAb與新生兒甲狀腺功能變化 胎兒約在12周齡時(shí)甲狀腺就已經(jīng)形成,垂體開始分泌TSH,且TSH水平高于母體,出生2 d后TSH水平逐漸降至成人水平。新生兒出生后1 h左右總?cè)饧紫僭彼?T3)、甲狀腺素(T4)驟升3~6倍,其后3~5 d逐漸下降;rT3則在出生后驟降,第5天降至成人水平[8]。目前,我國篩查新生兒甲狀腺功能減退一般是在出生后2~3 d以濾紙片采集足跟末梢血檢測TSH作為初篩,當(dāng)TSH>20 mU/L時(shí)再抽取新生兒靜脈血檢查甲狀腺功能,以進(jìn)一步確診。鑒于TPOAb對(duì)甲狀腺功能的影響,本研究在新生兒出生3~5 d時(shí)抽取靜脈血檢測甲狀腺功能、甲狀腺抗體作為初篩,對(duì)母體TPOAb陽性、甲狀腺功能、甲狀腺抗體異常的新生兒繼續(xù)隨訪,篩查出生1、3個(gè)月新生兒甲狀腺功能、甲狀腺抗體情況。由于妊娠期女性免疫系統(tǒng)處于抑制狀態(tài),其孕晚期TPOAb陽性率較孕早期降低[9],故根據(jù)產(chǎn)婦孕晚期TPOAb水平的不同將新生兒分為TPOAb高水平組及TPOAb中高水平組。本研究結(jié)果顯示,A1、A2亞組新生兒出生3~5 d時(shí)TPOAb、TGAb、TG水平較N組偏高,說明TPOAb可能來源于母體,雖然母親甲狀腺功能指標(biāo)處于參考范圍內(nèi),但TPOAb仍對(duì)胎兒甲狀腺功能造成了一定影響。本研究結(jié)果顯示,A1、A2亞組新生兒出生1個(gè)月FT4水平間無差異;A2亞組新生兒出生1個(gè)月TSH、TPOAb、TGAb、TG水平高于A1亞組。A1、A2亞組新生兒出生3個(gè)月FT4、TPOAb、TG水平間無差異;A2亞組新生兒出生1個(gè)月TSH、TGAb水平高于A1亞組。以上結(jié)果提示,新生兒3個(gè)月齡時(shí)甲狀腺功能指標(biāo)基本恢復(fù)至參考范圍,說明其出生后甲狀腺功能恢復(fù)滯后于TPOAb陰性產(chǎn)婦的后代,但并未造成永久性甲狀腺功能減退。ROVELLI等[10]對(duì)129例新生兒的回顧性調(diào)查研究得出,患自身免疫性甲狀腺炎的母親所生的新生兒,常在出生1個(gè)月內(nèi)出現(xiàn)短暫而輕度高于相應(yīng)年齡參考范圍上限的TSH血癥;而且,新生兒的甲狀腺功能與母親孕期左旋甲狀腺素替代治療無關(guān)。杜培宜等[11]將55例TPOAb、TGAb陽性妊娠婦女分為左旋甲狀腺素干預(yù)組與未干預(yù)組,并與健康妊娠婦女比較,結(jié)果顯示,左旋甲狀腺素干預(yù)組與未干預(yù)組后代不同于健康組后代的甲狀腺功能狀態(tài),胎兒出生后甲狀腺功能與母親甲狀腺自身抗體有關(guān)。
3.3 TPOAb對(duì)新生兒甲狀腺功能的影響 從本研究結(jié)果可以看出,母親孕晚期TPOAb高水平對(duì)新生兒甲狀腺功能的影響時(shí)間較母親孕晚期TPOAb中高水平長,大部分新生兒TSH水平在出生后3個(gè)月時(shí)才恢復(fù)至參考范圍(0.27~4.20 mU/L),但仍較孕晚期TPOAb中高水平母親娩出的新生兒高。雖然TPOAb高水平未造成新生兒永久性甲狀腺功能減退,但近年來研究發(fā)現(xiàn),骨密度及骨重建與TSH水平關(guān)系密切,而與甲狀腺激素水平無關(guān)[12-14]。高TPOAb水平對(duì)新生兒生長發(fā)育有無長久影響仍不確定[15],仍需長期調(diào)查隨訪研究進(jìn)一步證實(shí)。
綜上所述,產(chǎn)婦單純TPOAb陽性對(duì)新生兒甲狀腺功能仍舊有影響,且產(chǎn)婦TPOAb高水平對(duì)新生兒甲狀腺功能的影響時(shí)間更長。鑒于本研究樣本量小,且甲狀腺功能篩查費(fèi)用相對(duì)較高,是否必須對(duì)單純TPOAb陽性產(chǎn)婦的后代進(jìn)行早期甲狀腺功能及相關(guān)抗體的篩查,仍需要大樣本量臨床病例對(duì)照研究提供循證醫(yī)學(xué)證據(jù)。
作者貢獻(xiàn):張文娟提供文章構(gòu)思與設(shè)計(jì),對(duì)研究結(jié)果進(jìn)行分析,負(fù)責(zé)文章整體;苑曉超負(fù)責(zé)數(shù)據(jù)收集、整理,撰寫論文;李志紅負(fù)責(zé)研究的可行性分析、論文修訂及校對(duì)、質(zhì)量控制;夏麗芳、李瑞雪、尹飛負(fù)責(zé)數(shù)據(jù)收集及統(tǒng)計(jì)分析。
本文無利益沖突。
本研究不足之處:
關(guān)于甲狀腺過氧化物酶抗體水平對(duì)新生兒影響程度,本研究觀察時(shí)間較短,且觀察指標(biāo)較少,可能限制了深入討論。
[1]徐艷紅,吳藝捷,羅越,等.孕婦血清甲狀腺過氧化物酶抗體陽性對(duì)妊娠結(jié)局的影響[J].中華內(nèi)分泌代謝雜志,2012,28(5):377-381.DOI:10.3760/cma.j.issn.1000-6699.2012.05.004.
XU Y H,WU Y J,LUO Y,et al.Influence of positive serum thyroid peroxidase antibody on pregnancy outcomes[J].Chinese Journal of Endocrinology and Metabolism,2012,28(5):377-381.DOI:10.3760/cma.j.issn.1000-6699.2012.05.004.
[2]THANGARATINAM S,TAN A,KNOX E,et al.Association between thyroid autoantibodies and miscarriage and preterm birth:meta-analysis of evidence[J].BMJ,2011,342:d2616.DOI:10.1136/bmj.d2616.
[3]POP V J,DE VRIES E,VAN BAAR A L,et al.Materal thyroid peroxidase antibodies during pregnancy:a marker of impaired child development?[J].J Clin Endocrinol Metab,1995,80(12):3561-3566.DOI:10.1210/jcem.80.12.8530599.
[4]中華醫(yī)學(xué)會(huì)內(nèi)分泌學(xué)分會(huì),中華醫(yī)學(xué)會(huì)圍產(chǎn)醫(yī)學(xué)分會(huì).妊娠和產(chǎn)后甲狀腺疾病診治指南[J].中華內(nèi)分泌代謝雜志,2012,28(5):354-371.DOI:10.3760/cma.j.issn.1000-6699.2012.05.002.
Endocrinology society of Chinese Medical Association,Perinatal Society Medicine of Chinese Medical Association.Treatment guidelines of pregnancy and postpartum thyroiditis[J].Chinese Journal of Endocrinology and Metabolism,2012,28(5):354-371.DOI:10.3760/cma.j.issn.1000-6699.2012.05.002.
[5] 寧光,潘長玉,孟迅吾,等.臨床內(nèi)分泌學(xué)[M].上海:上??茖W(xué)技術(shù)出版社,2011:314-317.
NING G,PAN C Y,MENG X W,et al.Clinical endocrinology[M].Shanghai:Shanghai Science and Technology Press,2011:314-317.
[6]LI Y,SHAN Z,TENG W,et al.Abnormalities of maternal thyroid function during pregnancy affect neuropsychological development of their children at 25-30 months[J].Clin Endocrinol(Oxf),2010,72(6):825-829.DOI:10.1111/j.1365-2265.2009.03743.x.
[7]陳東,鄧大同,陳明衛(wèi),等.孕婦TPO抗體和新生兒甲狀腺功能關(guān)系探討[J].安徽醫(yī)藥,2011,15(9):1091-1093.DOI:10.3969/j.issn.1009-6469.2011.09.016.
CHEN D,DENG D T,CHEN M W,et al.Relationship between TPO antibodies of pregnant women and thyroid function of newborn babies[J].Anhui Medical and Pharmaceutical Journal,2011,15(9):1091-1093.DOI:10.3969/j.issn.1009-6469.2011.09.016.
[8]顏純,王慕逖.小兒內(nèi)分泌學(xué)[M].北京:人民衛(wèi)生出版社,2006:163-165.
[9]蔣怡雅,吳藝捷,徐艷紅,等.妊娠中晚期孕婦甲狀腺功能異常和自身抗體篩查的研究[J].中華內(nèi)分泌代謝雜志,2011,27(10):816-820.DOI:10.3760/cma.j.issn.1000-6699.2011.10.008.
JIANG Y Y,WU Y J,XU Y H,et al.Investigation onto thyroid dysfunction and autoantibody screening in second and third trimesters of pregnancy[J].Chinese Journal of Endocrinology and Metabolism,2011,27(10):816-820.DOI:10.3760/cma.j.issn.1000-6699.2011.10.008.
[10]ROVELLI R,VIGONE M C,GIOVANETTONI C,et al.Newborn of mothers affected by autoimmune thyroiditis:the importance of thyroid function monitoring in the first months of life[J].Ital J Pediatr,2010,36:24.DOI:10.1186/1824-7288-36-24.
[11]杜培宜,周瓊,鐘麗麗,等.甲狀腺自身抗體陽性婦女孕期干預(yù)對(duì)嬰兒甲狀腺功能的影響[J].中華內(nèi)分泌代謝雜志,2010,26(11):931-935.DOI:10.3760/cma.j.issn.1000-6699.2010.11.005.
DU P Y,ZHOU Q,ZHONG L L,et al.Effects of intervention in pregnant women with positive thyroid autoantibodies on thyroid function of babies[J].Chinese Journal of Endocrinology and Metabolism,2010,26(11):931-935.DOI:10.3760/cma.j.issn.1000-6699.2010.11.005.
[12]BAUER D C,ETTINGER B,NEVITT M C,et al.Risk for fracture in women with low serum levels of thyroid-stimulating hormone[J].Ann Intern Med,2001,134:561-568.
[13]MORRIS M S.The association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American women[J].Bone,2007,40:1128-1134.DOI:10.1016/j.bone.2006.12.001.
[14]ZOFKOVA I,HILL M.Biochemical markers of bone remodeling correlate negatively with circulating TSH in postmenopausal women[J].Endocr Regul,2008,42(2):121-127.
[15]羅艷,李穎,高軒,等.右歸丸聯(lián)合左旋甲狀腺素對(duì)妊娠期甲狀腺功能減退孕婦血清葉酸、甲狀腺激素及嬰兒智能的影響[J].疑難病雜志,2016,15(9):935-938,942.
EffectofMaternalThyroidPeroxidaseAntibodyLevelsonNeonatalThyroidFunction
ZHANGWen-juan,YUANXiao-chao,LIZhi-hong*,XIALi-fang,LIRui-xue,YINFei
DepartmentofEndocrinology(theSecond),BaodingFirstCentralHospital,Baoding071000,China
*Correspondingauthor:LIZhi-hong,Chiefphysician;E-mail:lizhihonglfz@126.com
ObjectiveTo assess the impact of maternal thyroid peroxidase antibody(TPOAb) levels on neonatal thyroid function.MethodsA total of 33 maternal women,who were positive for TPOAb alone,admitted to the Baoding First Central Hospital between January 2015 and June 2016,and met the inclusion criteria,were enrolled as a TPOAb-positive group.Thirty healthy pregnant women who deliveredat the same hospital during the same period were also recruited as a TPOAb-negative group.All maternal women were followed up until 6 months after delivery.Neonates were assigned into N(negative maternal TPOAb) or A(positive maternal TPOAb) groups according to maternal TPOAb levels during late pregnancy.The neonates in group A were further sub-divided into A1(TPOAb level,30-100 U/ml,n=21) and A2(TPOAb level,> 100 U/ml,n=12) subgroups according to maternal TPOAb levels during late pregnancy.Data regarding the assessment of neonatal birth were compared between N and A groups,and thyroid function and thyroid antibodies were tested and compared between neonates in group N and subgroups A1 and A2 3-5 days after birth and between subgroups A1 and A2 1 and 3 months after birth,including thyroid-stimulating hormone(TSH),free thyroxine(FT4),TPOAb,thyroglobulin antibody(TGAb) and thyroglobulin(TG).In addition,the association of TSH and FT4levels with age and TPOAb level,were also examined in maternal women positive for TPOAb 3-5 days after delivery.ResultsThere were no significant differences in Apgar score 1 min after birth,body length or body weight between groups N and A(P> 0.05).Serum TSH,TPOAb,TGAb and TG levels were all significantly greater in subgroups A1 and A2 than in group N 3-5 days after birth(P<0.05).FT4levels were significantly lower in subgroups A1 and A2 than in group N(P<0.05),while TSH,TPOAb,TGAb and TG levels were significantly higher in subgroup A2 than in subgroup A1.FT4levels were significantly lower in subgroup A2 than in subgroup A1(P<0.05).There were four lost to follow-up in subgroup A1 1 month after birth.There was no significant difference in neonatal FT4levels between subgroups A1 and A2 1 month after birth(P> 0.05),and significantly higher neonatal TSH,TPOAb,TGAb and TG levels were detected in subgroup A2 than in subgroup A1 1 month after birth(P<0.05).In addition,there were two neonates lost follow-up in subgroup A1 3 months after birth.There was no significant difference in neonatal FT4,TPOAb or TG levels between subgroups A1 and A2 3 months after birth(P> 0.05),and significantly higher neonatal TSH and TGAb levels were detected in subgroup A2 than in subgroup A1 3 months after birth(P<0.05).Pearson correlation analysis revealed that neonatal TSH and FT4levels 3-5 days after birth were positively correlated with maternal TPOAb levels(r=0.393 and 0.423,P<0.05 in each case).ConclusionMaternal positive TPOAb influences neonatal thyroid functions and a higher maternal TPOAb level exhibits a longer effect on neonatal thyroid function.
Pregnancy;Thyroid peroxidase antibody;Thyroid function tests;Infant
071000河北省保定市第一中心醫(yī)院內(nèi)分泌二科
*通信作者:李志紅,主任醫(yī)師;E-mail:lizhihonglfz@126.com
R 335.2
A
10.3969/j.issn.1007-9572.2017.00.200
張文娟,苑曉超,李志紅,等.產(chǎn)婦不同甲狀腺過氧化物酶抗體水平對(duì)新生兒甲狀腺功能的影響研究[J].中國全科醫(yī)學(xué),2017,20(36):4506-4510.[www.chinagp.net]
ZHANG W J,YUAN X C,LI Z H,et al.Effect of maternal thyroid peroxidase antibody levels on neonatal thyroid function[J].Chinese General Practice,2017,20(36):4506-4510.
2017-07-05;
2017-10-10)
毛亞敏)